FDA Clears Medigene's IND for TCR-T Therapy in Certain Advanced Solid Tumors
Medigene to evaluate TCR-T therapy MDG1015 in Phase I trial for advanced solid tumors, targeting NY-ESO-1/LAGE-1a in HLA-A*02+ patients. Trial EPITOME1015-I aims to assess safety, feasibility, and efficacy, with a 20-day manufacturing process. Data expected by end of 2025, contingent on additional funding.
© Copyright 2025. All Rights Reserved by MedPath